Clinical Value of <i>IL6R</i> Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis

Clinical Value of <i>IL6R</i> Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis

Tocilizumab is a first-line biologic disease-modifying anti-rheumatic drug (bDMARD) that inhibits the interleukin-6 (IL-6) pathway by antagonizing the IL-6 receptor (IL-6R). Tocilizumab is widely used to treat rheumatoid arthritis (RA), a prevalent autoimmune disease that can cause irreversible join...

Full description

Bibliographic Details
Main Authors: Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Díaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa, Héctor Corominas
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Personalized Medicine
Subjects:
<i>IL6R</i>
genetic variants
tocilizumab
toxicity
rheumatoid arthritis
predictive biomarkers
Online Access:https://www.mdpi.com/2075-4426/13/1/61

Similar Items

Similar Items